Full Library

Return to list of results

Applying mucosal barrier injury laboratory-confirmed bloodstream infection criteria in patients with solid tumors and hematologic malignancies: A retrospective cohort study looking for the real source of infection

RIS

Recommended format for most reference management software

BibTeX

Recommended format for BibTeX-specific software

Open in Zotero
View on zotero.org
Resource type
Journal Article
Authors/contributors
Title
Applying mucosal barrier injury laboratory-confirmed bloodstream infection criteria in patients with solid tumors and hematologic malignancies: A retrospective cohort study looking for the real source of infection
Abstract
We evaluated the interference of the mucosal barrier injury (MBI) laboratory-confirmed bloodstream infection (MBI-LCBI) criteria on the central-line–associated bloodstream infection (CLABSI) incidence density, and the proportion of catheter-related bloodstream infections (CRBSIs) among those classified as MBI. We detected 339 CLABSIs: 15.0% were classified as MBI-LCBIs, and among these, 19.6% were classified as CRBSIs.
Publication
Infection Control & Hospital Epidemiology
Date
2022-02-11
Pages
1-3
Journal Abbr
Infect. Control Hosp. Epidemiol.
DOI
10.1017/ice.2021.466
URL
https://www.cambridge.org/core/product/identifier/S0899823X21004669/type/journal_article
Accessed
2/17/22, 5:27 PM
ISSN
0899-823X, 1559-6834
Short Title
Applying mucosal barrier injury laboratory-confirmed bloodstream infection criteria in patients with solid tumors and hematologic malignancies
Language
en
Library Catalog
DOI.org (Crossref)
Citation
Puin da Silva, A. C., Vieira, M. F., Freire, M. P., Vaz, L., Bonazzi, P. R., Ibrahim, K. Y., Diz, M. D. P. E., Hoff, P. M., Pereira, J., Rocha, V. G., & Abdala, E. (2022). Applying mucosal barrier injury laboratory-confirmed bloodstream infection criteria in patients with solid tumors and hematologic malignancies: A retrospective cohort study looking for the real source of infection. Infection Control & Hospital Epidemiology, 1–3. https://doi.org/10.1017/ice.2021.466
PREVENTION
HEME-ONC AND CELLULAR THERAPIES
Link to this record
https://www.transplantid.net/7FPVQQG8